| 56 |
Entgegengehaltene Nichtpatentliteratur/Zitate,
vom Anmelder genannt |
CTNP |
ACTA PHARMACEUTICS JUGOSLAVICA, vol. 33, no. 3-4, 1983, pages 199 - 208 1;
BETTI, M., GAZZ. CHIM. ITAL., vol. 33 II, no. 2, 1903 1;
BIOMEDICAL CHROMATOGRAPHY, vol. 28, no. 1, 2014, pages 142 - 151 1;
BORST, P.: "Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?", OPEN BIOLOGY, vol. 2, no. 5, 2012, Retrieved from the Internet 1;
CHAUR, MANUEL N.; COLLADO, DANIEL; LEHN, JEAN-MARIE, CHEMISTRY - A EUROPEAN JOURNAL, vol. 17, no. 1, 2011, pages 248 - 258 1;
CHEMMEDCHEM, vol. 11, no. 12, 16 February 2016 (2016-02-16), pages 1284 - 1295 1;
CISAR, J. S.; CRAVATT, B. F, J. AM. CHEM. SOC., vol. 134, no. 25, 2012, pages 10385 - 10388 1;
EASMON ET AL., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 5, 1997, pages 397 - 408 1;
ENQUIST, P.A. ET AL., BIOORG MED CHEM LETT, vol. 22, no. 10, 2012, pages 3550 - 3 1;
FERNANDEZ-BACHILLER, M.I. ET AL., J MED CHEM, vol. 53, no. 13, 2010, pages 4927 - 37 1;
GILLET, J.-P.; VARMA, S.; GOTTESMAN, M.M.: "The Clinical Relevance of Cancer Cell Lines", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 105, no. 7, 2013, pages 452 - 458 1;
GOLDSBOROUGH, A.S ET AL.: "Collateral Sensitivity of Multidrug-Resistant Cells to the Orphan Drug Tiopronin", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 14, 2011, pages 4987 - 4997, XP055030262, DOI: doi:10.1021/jm2001663 1;
GOTTESMAN, M.M.; FOJO, T.; BATES, S.E.: "Multidrug resistance in cancer: role of ATP-dependent transporters", NAT REV CANCER, vol. 2, 2002, pages 48 - 58, XP009041990, DOI: doi:10.1038/nrc706 1;
HALL, M.D. ET AL.: "Synthesis and Structure-Activity Evaluation of lsatin-?-thiosemicarbazones with Improved Selective Activity toward Multidrug-Resistant Cells Expressing P-Glycoprotein", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 16, 2011, pages 5878 - 5889, XP055007622, DOI: doi:10.1021/jm2006047 1;
HALL, M.D. ET AL.: "Synthesis, Activity, and Pharmacophore Development for lsatin-?-thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, no. 10, 2009, pages 3191 - 3204 1;
HEFFETER, P. ET AL.: "Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24", BIOCHEMICAL PHARMACOLOGY, vol. 73, no. 12, 2007, pages 1873 - 1886, XP022062511, DOI: doi:10.1016/j.bcp.2007.03.002 1;
HERMAN TS; CRESS AE; GERNER EW.: "Collateral sensitivity to methotrexate in cells resistant to adriamycin", CANCER RES., vol. 39, 1979, pages 1937 - 42 1;
HETEROCYCLES, vol. 68, no. 3, 2006, pages 531 - 537 1;
HOMOLYA, L. ET AL.: "A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells", BR J CANCER, vol. 73, no. 7, 1996, pages 849 - 55, XP001073458 1;
J. MED. CHEM., vol. 56, no. 2, 2013, pages 521 - 533 1;
J. ORG. CHERN., vol. 26, 1961, pages 4078 - 4083 1;
J. VIROLOGY, vol. 84, no. 7, 2010, pages 3408 - 3412 1;
JANSSON, P.J. ET AL.: "Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 15, 2015, pages 9588 - 9603, XP055296022, DOI: doi:10.1074/jbc.M114.631283 1;
KAMIYAMA, HIROHIKO ET AL.: "Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice", CLIN CANCER RES, vol. 19, 2013, pages 1139 - 1146 1;
LI, L.; B. XU, TETRAHEDRON, vol. 64, no. 49, 2008, pages 10986 - 10995 1;
LIBBY, E; HROMAS, R.: "Dismounting the MDR horse", BLOOD, vol. 116, no. 20, 2010, pages 4037 - 4038 1;
LUDWIG, J.A. ET AL.: "Selective Toxicity of NSC73306 in MDR1-Positive Cells as a New Strategy to Circumvent Multidrug Resistance in Cancer", CANCER RESEARCH, vol. 66, no. 9, 2006, pages 4808 - 4815, XP055030711, DOI: doi:10.1158/0008-5472.CAN-05-3322 1;
M MOVRIN, D.; MAYSINGER, E. M, PHARMAZIE, vol. 35, 1980, pages 458 - 460 1;
MANNICH, C.; KROSCHE, W., ARCHIV DER PHARMAZIE, vol. 250, 1912, pages 647 - 667 1;
MARTIN, E.W.: "Remington's Pharmaceutical Sciences", 1995 1;
N RISCH ET AL., ANGEW. CHEM. INT. ED., vol. 37, 1998, pages 1044 - 1070 1;
NAKAGAWA-GOTO, K. ET AL.: "Antitumor Agents. 280. Multidrug Resistance-Selective Desmosdumotin B Analogues", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 18, 2010, pages 6699 - 6705 1;
NEGM, N.A.; S.M. MORSY; M.M. SAID, BIOORG MED CHEM, vol. 13, no. 21, 2005, pages 5921 - 6 1;
OJAIMI, INORG. CHEM., vol. 50, 2011, pages 10966 - 10973 1;
ORINA, J.N. ET AL.: "Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database", MOLECULAR CANCER THERAPEUTICS, vol. 8, no. 7, 2009, pages 2057 - 2066, XP002592580, DOI: doi:10.1158/1535-7163.MCT-09-0256 1;
P. H. STAHL; C.G. WERMUTH: "Handbook of Pharmaceutical Salts", 2008, WILEY 1;
PAJIC, M. ET AL.: "Moderate increase in Mdr1a/1 b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer", CANCER RESEARCH, vol. 69, no. 16, 2009, pages 6396 - 6404 1;
PAPE VFS; TURK D; SZABO P; WIESE M; ENYEDY EA; SZAKACS G: "Synthesis and characterization of the anticancer and metal binding properties of novel pyrimidinylhydrazone derivatives", J. INORG. BIOCHEM., vol. 144, 2015, pages 18 - 30, XP029188548, DOI: doi:10.1016/j.jinorgbio.2014.12.015 1;
PETITJEAN, A.; N. KYRITSAKAS; J.M. LEHN, CHEMISTRY - A EUROPEAN JOURNAL, vol. 11, no. 23, 2005, pages 6818 - 28 1;
ROTTE'NBERG, S; BORST, P.: "Drug resistance in the mouse cancer clinic", DRUG RESISTANCE UPDATES, 20 February 2012 (2012-02-20), Retrieved from the Internet 1;
SARKADI, B ET AL.: "Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system", PHYSIOLOGICAL REVIEWS, vol. 86, no. 4, 2006, pages 1179 - 1236 1;
SHAW, A.Y. ET AL., EUR J MED CHEM, vol. 45, no. 7, 2010, pages 2860 - 7 1;
SOSIC, I. ET AL., J MED CHERN, vol. 56, no. 2, 2013, pages 521 - 33 1;
SZAKACS, G ET AL.: "Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance", CHEMICAL REVIEWS, 2014 1;
SZAKACS, G. ET AL.: "Targeting multidrug resistance in cancer", NAT REV DRUG DISCOV, vol. 5, no. 3, 2006, pages 219 - 34, XP002513064, DOI: doi:10.1038/nrd1984 1;
SZAKACS, G.; ANNEREAU, J.-P.; LABABIDI, S.; SHANKAVARAM, U.; ARCIELLO, A.; BUSSEY, K.J. ET AL.: "Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells", CANCER CELL, vol. 6, no. 2, 2004, pages 129 - 137 1;
SZATMARI, I.; F. FULOP, TETRAHEDRON, vol. 69, no. 4, 2013, pages 1255 - 1278 1;
SZATMARI, I.; L. LAZAR; F. FULOP, TETRAHEDRON LETTERS, vol. 47, no. 23, 2006, pages 3881 - 3883 1;
SZYBALSKI, W.; BRYSON, V.: "Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics", JOURNAL OF BACTERIOLOGY, vol. 64, no. 4, 1952, pages 489 - 499 1;
TERRY; RUDOLPH F. PRZYSTAL J.P. PHILLIPS, J. MED. CHEM., vol. 10, no. 5, September 1967 (1967-09-01), pages 981 - 981 1;
TRAMONTINI, M; ANGIOLINI,L: "Mannich-Bases, Chemistry and Uses", 1994, CRC 1;
TRUDOVE NA NAUCHNOIZSLEDOVATELSKIYA KHIMIKOFARMATSEVTICHEN INSTITUT, vol. 15, 1985, pages 71 - 80 1;
TURK, D. ET AL.: "Identification of Compounds Selectively Killing Multidrug-Resistant Cancer Cells", CANCER RESEARCH, vol. 69, no. 21, 2009, pages 8293 - 8301, XP002592581, DOI: doi:10.1158/0008-5472.CAN-09-2422 1;
TURK, D.; SZAKACS, G.: "Relevance of multidrug resistance in the age of targeted therapy", CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, vol. 12, no. 2, 2009, pages 246 - 252, XP009136636 1;
UJHELLY O; OZVEGY C; VARADY G ET AL.: "Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cells", HUM GENE THER, vol. 14, pages 403 - 12 1;
WADA ET AL., CHEMICAL COMMUNICATIONS, vol. 48, no. 43, 2012, pages 5340 - 5342 1;
WANGTRAKULDEE, P. ET AL., ACS MED CHEM LETT, vol. 4, no. 8, 2013 1;
WU, QIONG ET AL.: "Multidrug-resistance in cancer chemotherapeutics: Mechanisms and lab approaches", CANCER LETTERS, vol. 347, no. 2, 2014, pages 159 - 166 1
|
